What is Avasa?
Avasa is a burgeoning medical device startup established in 2018, headquartered in New Zealand. The company is on the cusp of launching its flagship product, the Avasa Coupler. This innovative device is engineered to standardize and streamline the intricate process of arterial reconnections, a critical procedure in reconstructive microsurgery. The company's focus on this specialized niche positions it to address unmet needs within the surgical technology market.
How much funding has Avasa raised?
Avasa has raised a total of $1.6M across 1 funding round:
Other Financing Round
$1.6M
Other Financing Round (2023): $1.6M with participation from The NZGCP, Brisbane Angels, and Pacific Channel
Key Investors in Avasa
The NZGCP
The NZGCP is a New Zealand-based entity that supports technology companies through various funding options, including seed and venture funds, aiming to foster global success for Kiwi tech firms.
Brisbane Angels
Brisbane Angels is a prominent angel investing group in Australia, focusing on early-stage, high-growth startups and providing seed funding to visionary founders.
Pacific Channel
Pacific Channel is an Asia-Pacific funds management firm specializing in deep-tech and venture capital, particularly in health and environmental sectors, supporting companies from pre-seed to Series A.
What's next for Avasa?
With the recent infusion of capital, Avasa is poised to accelerate its product launch and market penetration strategies. The company's trajectory suggests a focus on scaling operations, further research and development, and potentially expanding its product portfolio within the reconstructive microsurgery domain. This strategic backing from prominent investors indicates confidence in Avasa's technological advancements and its potential to capture a significant share of the medical device market.
See full Avasa company page
